This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q21.3 | Special Copayment Reduction: V269 (rare disease special copayment reduction) |
| B. Synonyms | Tetralogy of Fallot, Fallot's tetralogy, ventricular septal defect with pulmonary stenosis or atresia, overriding aorta, and right ventricular hypertrophy (VSD with PS/PA, overriding aorta, RVH) |
| C. Adult onset | Possible first onset in adulthood: low — as a cyanotic congenital heart disease, it is mostly diagnosed in the neonatal and infant period. However, many adult patients after corrective surgery present for the first time in adulthood with symptoms (exercise intolerance, syncope) as pulmonary regurgitation, right ventricular dysfunction, and arrhythmia progress. One of the most common diagnoses in ACHD clinics. |
| 1. History | 1888 Fallot's systematic classification → 1944 Blalock-Taussig shunt → 1954 Kirklin's complete repair → 2000s transcatheter pulmonary valve replacement (Melody/SAPIEN). |
| 2. Causes | Anterosuperior deviation of the embryonic conotruncal septum → VSD + RVOTO + RVH + overriding aorta. 22q11.2 deletion (DiGeorge syndrome, 15~20%). NKX2.5, GATA4, JAG1 variants. |
| 3. Genetics | 22q11.2 deletion is the most common associated genetic abnormality (15~20%). TBX1 is the key gene. Familial recurrence rate 2~5%. 22q11.2 deletion testing is recommended for all patients. |
| 4. General epidemiology | The most common cyanotic congenital heart disease (7~10% of all CHD). 1 in 2,500~3,600 live births. Korean special copayment reduction code V269. One of the most common single diagnoses in ACHD. |
| 5. Pathophysiology | RVOTO → right-to-left shunt → cyanosis. Hypercyanotic spell (Tet spell): outflow tract spasm → decreased pulmonary blood flow vicious cycle. After repair: transannular patch → pulmonary regurgitation → right ventricular volume overload → dysfunction. |
| 6. Symptoms | Neonates: cyanosis (depending on the degree of RVOTO). Infancy: hypercyanotic spell (Tet spell). Children: exercise intolerance, clubbing, polycythemia. Adults after repair: exercise intolerance, arrhythmia, syncope. |
| 7. Signs | Cyanosis, clubbing, systolic murmur, decreased P2. ECG: right axis deviation, right ventricular hypertrophy. After repair: prolonged QRS duration (≥180ms) is a sudden death risk indicator. MRI: PR fraction, right ventricular EDV index. |
| 8. Screening | Prenatal fetal echocardiography (18~22 weeks). Neonatal CCHD oxygen saturation screening. 22q11.2 deletion testing (FISH/CMA): performed in all patients. |
| 9. Diagnosis | Echocardiography (RVOTO location and pressure gradient, VSD, pulmonary arteries). Cardiac CT (pulmonary artery branches, coronary arteries). Cardiac MRI (PR fraction after repair, right ventricular EDV/EF). 22q11.2 deletion testing. |
| 10. Treatment | Complete repair (at 3~6 months of age). Transannular patch vs valve-sparing. PVR for pulmonary regurgitation after repair (surgical/transcatheter Melody·SAPIEN). Arrhythmia: ICD, catheter ablation. |
| 11. Prognosis | Survival after repair is 95~98% at 10 years and 80~90% at 30 years. Sudden death risk (0.1~0.2% per year). Major long-term factors: pulmonary regurgitation, right ventricular function, QRS duration, arrhythmia. |
| 12. Prevention | Prenatal diagnosis and confirmation of 22q11.2. Education on managing Tet spells. After repair: regular MRI, QRS surveillance, timely pulmonary valve replacement, prevention of infective endocarditis. |
| 13. References | List of 10 key references |
Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart disease, and its history goes back to the late 19th century. In 1888, the French physician Étienne-Louis Arthur Fallot (1850~1911) systematically described the four anatomical features of this cardiac malformation, then known as 'maladie bleue (blue disease)', and published a paper classifying it as a single entity, which is how the disease came to bear his name. Fallot emphasized that the four features of ventricular septal defect (VSD), pulmonary stenosis (PS), right ventricular hypertrophy (RVH), and overriding aorta always occur together.
However, there were predecessors who described this malformation before Fallot. In 1672, the Danish anatomist Nicolaus Steno first described a similar cardiac malformation, and in 1784 the Englishman John Hunter also reported the same malformation. Fallot's contribution was to link the clinical and pathological aspects through a systematic pathoanatomical classification.
The most epoch-making event in the history of surgical treatment was the Blalock-Taussig shunt (BT shunt) developed in 1944 by Alfred Blalock, Helen Taussig, and the surgical technician Vivian Thomas. This operation is a palliative shunt procedure that connects the subclavian artery to the pulmonary artery to increase pulmonary blood flow; by relieving cyanosis, it saved thousands of lives. This operation is regarded as the starting point of the history of congenital heart surgery.
In 1954, John Kirklin performed the world's first successful complete repair of TOF using cardiopulmonary bypass. Over the following decades, surgical techniques advanced, and complete repair at 3~6 months of age is now the standard. In the 1970s, the transannular patch right ventricular outflow tract reconstruction was introduced and greatly improved the success rate of complete repair, but this method became the cause of a long-term complication, pulmonary regurgitation.
Since the 2000s, percutaneous pulmonary valve replacement (PPVR: Melody or SAPIEN valve) has been developed, making it possible to replace the pulmonary valve without reoperation, which changed the paradigm of managing adult TOF patients. TOF is now established as a disease with long-term survival after the initial surgery, and it is one of the diseases most frequently followed in the field of adult congenital heart disease (ACHD).
The cause of tetralogy of Fallot is explained by abnormal development of the conotruncal septum during embryonic development. Normally, the conotruncal septum (conal septum, infundibular septum) should develop in an anterior position and divide the ventricular outflow tracts and the pulmonary artery and aorta evenly, but in TOF this septum is deviated anterosuperiorly (anterosuperior deviation), producing the following four anatomical abnormalities simultaneously.
First, ventricular septal defect (VSD): deviation of the conotruncal septum forms a large non-restrictive perimembranous or infundibular VSD. Blood shunts from the right ventricle to the left ventricle through this defect. Second, pulmonary stenosis or right ventricular outflow tract obstruction (RVOTO): the deviated septum narrows the right ventricular outflow tract, the pulmonary valve is bicuspid or narrowed, and the pulmonary trunk and branches may also be narrowed. Third, right ventricular hypertrophy (RVH): a secondary result of the increased right ventricular pressure caused by pulmonary stenosis. Fourth, overriding aorta: the aorta straddles the VSD and receives blood from both ventricles.
As a genetic cause, 22q11.2 deletion (DiGeorge/velocardiofacial syndrome) is the most important and is found in about 15~20% of TOF patients. The TBX1 gene at 22q11.2 plays a key role in the development of the cardiac outflow tract, and deletion of a single copy of this gene causes abnormal development of the conotruncal septum. In addition, 8p23.1 (GATA4), 10p13, JAG1 (Alagille syndrome), and other complex chromosomal abnormalities have also been reported. De novo variants such as CHD7, NKX2.5, and GATA4 are identified in about 10~15% of patients with isolated TOF. As environmental factors, early-pregnancy diabetes, high-concentration oxygen therapy for retinal abnormalities, and fever during pregnancy have been reported as general risk factors for congenital heart disease.
The most important aspect of the genetics of tetralogy of Fallot is the microdeletion at band 1, region 1 of the long arm of chromosome 22 (22q11.2 deletion). This deletion is found in about 15~20% of TOF patients, and patients carrying it are diagnosed with DiGeorge syndrome/velocardiofacial syndrome (VCFS)/22q11.2 deletion syndrome. The deletion is about 3 Mb in size and includes TBX1, CRKL, and about 30~40 other genes. TBX1 is a T-box transcription factor that regulates development of the cardiac conotruncus, and loss of a single copy of this gene is the main cause of conotruncal malformations, including TOF.
Besides TOF, symptoms that may occur in 22q11.2 deletion syndrome include hypoparathyroidism (hypocalcemia, neonatal seizures), T-cell immunodeficiency due to thymic hypoplasia, palatal abnormalities (cleft palate or velopharyngeal dysfunction), characteristic facial features, learning disabilities, and psychiatric abnormalities (schizophrenia, ADHD, anxiety disorders). More than 90% of 22q11.2 deletions arise de novo, but in about 10% the deletion is familial, with one parent carrying it. The risk of transmission to the child from a parent carrying the deletion is 50%.
Besides 22q11.2 deletion, various genetic variants are associated with isolated TOF. NKX2.5 (5q35.1) is a cardiac transcription factor, and heterozygous variants are associated with various congenital heart diseases (TOF, ASD, VSD). GATA4 (8p23.1) is a transcription factor in cardiac development, and variants associated with TOF have been reported. JAG1 variants are associated with TOF or pulmonary stenosis in Alagille syndrome. In genetic testing including whole-exome sequencing, a causative genetic variant is identified in about 25~30% of TOF patients.
The familial recurrence rate of isolated TOF is about 2~5%, and when a 22q11.2 deletion is confirmed, the risk of recurrence in children is 50%. Testing for 22q11.2 deletion (FISH, MLPA, CMA) in all TOF patients is standard clinical practice. When a deletion is confirmed, 22q11.2 testing of the parents, genetic counseling, and prenatal diagnosis in the next pregnancy are recommended.
Tetralogy of Fallot is the most common cyanotic congenital heart disease, accounting for about 7~10% of all congenital heart disease. It occurs in about 1 in 2,500~3,600 live births, and more than 50,000 newborns worldwide are diagnosed with TOF each year. There is no significant difference in occurrence by sex, although some studies report a slightly higher frequency in males.
Geographic and ethnic differences in incidence are not clear, and TOF occurs equally in all ethnic groups worldwide. It is also associated with Down syndrome, and TOF accompanies about 5~8% of patients with Down syndrome. In TOF patients with accompanying 22q11.2 deletion syndrome, non-cardiac abnormalities related to DiGeorge syndrome (hypocalcemia, immunodeficiency, palatal abnormalities) must be managed together.
Epidemiology in Korea: in domestic single-center and registry studies of congenital heart disease, TOF accounts for about 5~8% of all congenital heart disease. According to Health Insurance Review & Assessment Service (HIRA) data, patients registered under code Q21.3 can receive rare disease medical expense support under special copayment reduction code V269. Since early surgical repair became standardized, complete repair at 3~6 months of age has become common in Korea as well, and the number of long-term survivors after repair is increasing.
The prognosis of TOF patients left without surgical repair was very poor. In historical natural history studies, more than 50% of patients with unrepaired TOF died before age 10. Now the number of patients surviving more than 30~40 years after repair is increasing, and adult TOF patients have become one of the single diagnoses making up the largest proportion in adult congenital heart disease (ACHD) clinics. The main challenges in long-term follow-up are pulmonary regurgitation, right ventricular dysfunction, arrhythmia, and reoperation or transcatheter pulmonary valve replacement.
The core pathophysiology of tetralogy of Fallot is determined by the degree of right ventricular outflow tract obstruction (RVOTO) and the amount of right-to-left shunt through the VSD. The severity of RVOTO at birth is the most important factor determining the clinical course.
Mechanism of cyanosis: when right ventricular pressure increases because of pulmonary stenosis, a right-to-left shunt occurs through the VSD and venous blood enters the systemic circulation. Because the aorta overrides the VSD and receives blood from both ventricles, blood flow from the right ventricle to the pulmonary artery decreases and unoxygenated blood flows directly into the aorta. The more severe the RVOTO, the more pulmonary blood flow decreases and the more severe the cyanosis becomes.
Hypercyanotic spell ("Tet spell"): a characteristic acute complication of TOF, in which autonomic stimulation such as crying, feeding, defecation, or exertion triggers spastic contraction of the right ventricular outflow tract muscle (infundibulum), causing pulmonary blood flow to decrease abruptly. As a result, cyanosis suddenly worsens, and hyperpnea, loss of consciousness, and in severe cases even seizures and death may follow. The key mechanism of the hypercyanotic spell is a vicious cycle of right ventricular outflow tract spasm and the resulting decrease in pulmonary blood flow. Treatment consists of the knee-chest position, oxygen supply, morphine (or fentanyl), propranolol (a beta blocker, to relax the right ventricular outflow tract), and phenylephrine (to increase systemic vascular resistance).
Pathophysiology after repair: the most important pathophysiological change after complete repair is pulmonary regurgitation (PR). Because right ventricular outflow tract reconstruction (especially a transannular patch) abolishes pulmonary valve function, moderate to severe PR develops in most patients after repair surgery. Chronic PR places a volume overload on the right ventricle, causing the right ventricle to dilate and systolic function to decline. Right ventricular dilation and dysfunction increase the risk of arrhythmia (especially ventricular tachycardia), heart failure, and sudden death. When residual RVOTO (restrictive) is present, pulmonary stenosis and regurgitation can combine to place pressure and volume overload on the right ventricle simultaneously.
Symptoms of tetralogy of Fallot vary greatly with the degree of RVOTO, whether surgical repair has been performed, and the time elapsed since repair.
Neonatal and infant symptoms: when RVOTO is severe, cyanosis appears immediately after birth or within a few days. When pulmonary stenosis is extreme and close to pulmonary atresia, survival depends on pulmonary blood flow via the ductus arteriosus, and cyanosis suddenly worsens when the ductus arteriosus closes. When RVOTO is mild, cyanosis is absent or minimal initially, which is called 'pink Tet'.
Hypercyanotic spell (Tet spell): most common in infancy (2 months to 2 years of age) before corrective surgery. It presents as sudden worsening of cyanosis and hyperpnea followed by limpness after crying, feeding, defecation, or waking. The squatting position, pulling the knees to the chest, is an instinctive response that raises systemic vascular resistance and reduces the right-to-left shunt. In a child before corrective surgery, hypercyanotic spells recurring at intervals of several hours are an indication for emergency surgery.
Childhood symptoms: in unrepaired children, worsening cyanosis on exertion, exercise intolerance, failure to thrive, and clubbing occur. Polycythemia develops as a compensatory response to chronic hypoxemia, increasing the risk of headache, hyperviscosity thrombosis, and stroke.
Adult symptoms after repair: after a long asymptomatic period following repair, exercise intolerance, dyspnea, fatigue, palpitations, and syncope appear as right ventricular dysfunction due to chronic pulmonary regurgitation progresses. When arrhythmias such as atrial fibrillation, atrial flutter, or ventricular tachycardia occur, they cause sudden palpitations or syncope. These symptoms become an indication for pulmonary valve replacement (surgical or transcatheter).
Physical and test findings in tetralogy of Fallot vary with whether the patient is before or after repair, the degree of cyanosis, and right ventricular function.
Physical signs (before repair): cyanosis and clubbing are characteristic. A strong systolic murmur (an ejection murmur from pulmonary stenosis or a VSD murmur) is heard at the lower left sternal border. Because pulmonary blood flow is reduced, the pulmonic sound (P2) is decreased or absent. There is a paradoxical relationship in which the murmur intensity weakens as RVOTO becomes more severe. During a hypercyanotic spell, the murmur suddenly disappears (the murmur disappears when outflow tract spasm reduces pulmonary blood flow). ECG: right axis deviation, findings of right ventricular hypertrophy. Chest X-ray: 'boot-shaped (coeur en sabot)' cardiac silhouette (concave pulmonary segment, right ventricular hypertrophy), decreased pulmonary vascular markings.
Physical signs (after repair): a diastolic murmur due to pulmonary regurgitation may be heard at the left sternal border. In severe pulmonary regurgitation, the pulmonary regurgitation murmur becomes weak or disappears (free PR). P2 is decreased or absent. A parasternal heave due to right ventricular dilation may be palpable. ECG: prolonged QRS duration (≥180 ms) is important as a surrogate indicator of right ventricular dysfunction and sudden death risk. Incomplete or complete right bundle branch block pattern. Chest X-ray: cardiomegaly (right ventricular dilation).
Echocardiographic findings (after repair): assess the degree of pulmonary regurgitation (color Doppler, shortened PR pressure half-time on CW Doppler = free PR), right ventricular size and function, residual VSD, residual RVOTO pressure gradient, and size of the pulmonary trunk and branches. Right ventricular dysfunction: decreased TAPSE, decreased RV FAC.
Cardiac MRI findings (after repair): pulmonary regurgitation fraction (PR fraction), right ventricular EDV index (>150 mL/m²), decreased right ventricular EF (<45%), and right ventricular myocardial fibrosis are used to decide the timing of pulmonary valve replacement. In the 2014 consensus criteria on timing of pulmonary valve replacement in TOF, CMR measurements were included as key evidence.
Tetralogy of Fallot is a cyanotic congenital heart disease and is likely to be detected by newborn oxygen saturation screening (CCHD screening program). However, in 'pink Tet' with mild RVOTO, the initial oxygen saturation may be normal, so clinical vigilance is needed.
Prenatal fetal echocardiography: TOF is suspected when abnormalities of the ventricular outflow tract (unequal sizes of the great vessels, ventricular septal defect, overriding aorta) are observed on detailed fetal echocardiography at 18~22 weeks of gestation. Assessment of pulmonary artery branch size, pulmonary valve morphology, and Doppler of pulmonary artery flow is important. When TOF is diagnosed prenatally, testing for 22q11.2 deletion (amniocentesis or CVS) is recommended.
Newborn CCHD screening (oxygen saturation screening): cyanotic congenital heart diseases such as TOF are detected by newborn oxygen saturation screening programs conducted in the United States (since 2011), Korea (since 2016), and elsewhere. The positive criteria are SpO2 < 95% (right hand or foot) or a difference between the two sites > 3%, and any abnormal finding is immediately confirmed by echocardiography.
22q11.2 deletion testing: screening for 22q11.2 deletion (FISH or CMA) is performed in all TOF patients. In patients with the deletion, multidisciplinary evaluation of hypocalcemia (a cause of neonatal seizures), immune dysfunction, and palatal abnormalities is additionally needed. Genetic test results have an important influence on postoperative management (immunization, use of irradiated blood, etc.) and genetic counseling.
Diagnosis of tetralogy of Fallot is established by echocardiography, and detailed anatomical assessment for surgical planning and confirmation of associated abnormalities (genetic, other malformations) are needed.
Transthoracic echocardiography (TTE): assesses the location and size of the ventricular septal defect, location of pulmonary stenosis (subvalvular/valvular/supravalvular/pulmonary artery branch) and pressure gradient (Doppler CW), degree of overriding aorta, right ventricular size and hypertrophy, pulmonary valve morphology, pulmonary artery branch size, and left ventricular function. Color Doppler confirms the direction of VSD shunting (a right-to-left shunt causes cyanosis) and pulmonary blood flow.
Cardiac CT angiography (CTA): essential for anatomical assessment of the pulmonary artery branches (left and right pulmonary artery branches, segmental pulmonary arteries). Important for identifying coronary artery anomalies (in about 5~10% of TOF, the left anterior descending artery has an anomalous course crossing the right ventricular outflow tract, with a risk of injury during surgery). A low-dose protocol is used to minimize radiation exposure.
Cardiac MRI (CMR): the key test for long-term follow-up after repair. It quantifies pulmonary regurgitation fraction, right ventricular EDV index, ESV index, and EF, left ventricular function, and myocardial fibrosis (LGE). It is used to decide the timing of pulmonary valve replacement (right ventricular EDV index > 150~160 mL/m², EF < 45%, progressive right ventricular dysfunction).
Electrophysiology study and Holter: important for assessing arrhythmia after repair (ventricular tachycardia, atrial fibrillation, atrioventricular block). QRS duration > 180 ms is known as an independent risk factor for ventricular tachycardia and sudden death. Exercise stress ECG is also useful for assessing whether arrhythmia is provoked.
22q11.2 deletion testing: uses FISH (fluorescence in situ hybridization) or chromosomal microarray (CMA). When a deletion is confirmed, assessment of parathyroid function (serum calcium, PTH), immune function (lymphocyte count, T-cell subsets), palatal structure (nasopharyngoscopy), and neurodevelopment is needed.
Treatment of tetralogy of Fallot centers on complete repair surgery, and long-term management of pulmonary regurgitation and arrhythmia surveillance after repair are key.
Complete repair: the current standard is to perform primary complete repair at 3~6 months of age. The components of the operation are ① VSD patch closure and ② right ventricular outflow tract reconstruction (infundibular muscle resection, pulmonary valve repair, or transannular patch). If there is an anomalous coronary course (when the anterior descending artery crosses the right ventricular outflow tract), an external conduit (right ventricle-pulmonary artery conduit) is inserted. A transannular patch (TAP) effectively relieves right ventricular outflow tract narrowing but causes pulmonary regurgitation. When valve-sparing repair is possible, pulmonary valve function is preserved to minimize long-term PR complications.
Palliative procedure (temporary shunt surgery): in low-birth-weight infants, extremely premature infants, or when the pulmonary artery branches are very small, pulmonary blood flow is secured with a modified Blalock-Taussig shunt (modified BT shunt: connecting the subclavian artery to the pulmonary artery with a Gore-Tex vascular graft) and, after the pulmonary arteries have grown, complete repair is planned. Percutaneous right ventricular outflow tract balloon angioplasty is used as a palliative measure before complete repair in some selected patients.
Pulmonary valve replacement (PVR): indicated when right ventricular dysfunction progresses because of moderate to severe PR after repair. Indications: right ventricular EDV index > 150 mL/m², right ventricular EF < 45%, progressive right ventricular dysfunction, appearing together with symptoms (exercise intolerance, heart failure, arrhythmia). Surgical PVR: the pulmonary valve is replaced with a bioprosthetic or mechanical valve. Transcatheter PVR (TPVR): a Melody valve (Medtronic) or SAPIEN XT/3 (Edwards) valve is inserted percutaneously into a conduit or the right ventricular outflow tract; because reintervention is possible without surgery, it is now actively used in adult TOF patients.
Arrhythmia treatment: for ventricular tachycardia and atrial fibrillation/flutter, antiarrhythmic drugs (amiodarone, sotalol), catheter ablation, or ICD implantation are considered. ICD implantation is considered as an indication in patients with QRS duration > 180 ms, inducible ventricular tachycardia, right ventricular dysfunction, or a history of syncope.
Tetralogy of Fallot is a disease with long-term survival after complete repair, and a considerable number of patients worldwide survive more than 30~40 years after repair. Survival after repair is reported at about 95~98% at 10 years and about 80~90% at 30 years.
Pulmonary regurgitation and right ventricular function: the most important long-term prognostic factor after repair. Right ventricular dilation and dysfunction due to chronic pulmonary regurgitation (almost unavoidable, especially when a transannular patch was used) progress over decades. Timely pulmonary valve replacement (surgical or transcatheter) can reverse or slow right ventricular dysfunction, but recovery is incomplete once severe right ventricular dysfunction has already developed. Therefore, performing timely pulmonary valve replacement while right ventricular function is preserved is the key strategy for improving prognosis.
Sudden death risk: sudden cardiac death (SCD) is an important cause of death in adult patients after TOF repair. The annual risk of sudden death is estimated at about 0.1~0.2%, and major risk factors are severe pulmonary regurgitation, right ventricular dysfunction, residual pulmonary stenosis, QRS duration ≥ 180 ms, inducible ventricular tachycardia, and a previous history of syncope.
Arrhythmia: in long-term follow-up after repair, the incidence of atrial fibrillation/flutter and ventricular tachycardia increases. Right atrial dilation, surgical scarring, and right ventricular dysfunction form the arrhythmic substrate. Sustained ventricular tachycardia is clinically important because it is directly linked to sudden death.
Prognosis in patients with 22q11.2 deletion: cardiac prognosis is similar to that of patients without the deletion, but non-cardiac problems (infections from immunodeficiency, hypocalcemia, psychiatric abnormalities, learning disabilities) affect overall quality of life. Psychiatric problems (schizophrenia, bipolar disorder) occur in adulthood at a high rate of about 25~30%, so mental health monitoring is important.
There is no established method to prevent the occurrence of tetralogy of Fallot itself, but early management preparation through prenatal diagnosis, early identification of 22q11.2 deletion, prevention of and immediate response to hypercyanotic spells, and prevention of complications through long-term follow-up after repair are important.
Prenatal diagnosis and confirmation of 22q11.2 deletion: when TOF is suspected on detailed fetal echocardiography during pregnancy, amniocentesis for 22q11.2 deletion testing is recommended. When a deletion is confirmed, comprehensive genetic counseling on recurrence risk and non-cardiac abnormalities is provided to the parents.
Education on preventing hypercyanotic spells and emergency response: parents of children before repair are taught how to recognize a hypercyanotic spell (sudden worsening of cyanosis, hyperpnea, limpness) and the initial response (knee-chest position, going to the emergency room immediately). Recurrent spells become an indication for early complete repair. Administration of a beta blocker (propranolol) to prevent recurrent spells may be considered before surgery.
Long-term follow-up after repair (prevention of complications): at a specialized ACHD center, right ventricular dysfunction and arrhythmia are detected early by regular cardiac MRI (every 2~3 years), ECG (QRS duration surveillance), Holter, and cardiopulmonary exercise testing, and pulmonary valve replacement or arrhythmia treatment is performed in a timely manner. Antibiotic prophylaxis before dental procedures to prevent infective endocarditis is given according to indications. Strenuous competitive sports are restricted when right ventricular dysfunction is severe. Assessment of ventricular function before pregnancy and multidisciplinary counseling are essential.
Apitz C, Webb GD, Redington AN. Tetralogy of Fallot. Lancet. 2009;374(9699):1462-1471. DOI: 10.1016/S0140-6736(09)60657-7. PMID: 19683908.
Bertranou EG, Blackstone EH, Hazelrig JB, Turner ME, Kirklin JW. Life expectancy without surgery in tetralogy of Fallot. Am J Cardiol. 1978;42(3):458-466. DOI: 10.1016/0002-9149(78)90941-4. PMID: 101761.
Blalock A, Taussig HB. The surgical treatment of malformations of the heart in which there is pulmonary stenosis or pulmonary atresia. JAMA. 1945;128(3):189-202. DOI: 10.1001/jama.1945.02860200029009.
Levi DS, Alejos JC, Moore JW. Future of interventional cardiology in pediatrics. Curr Opin Cardiol. 2003;18(2):79-90. DOI: 10.1097/00001573-200303000-00005. PMID: 12578002.
Geva T, Sandweiss BM, Gauvreau K, et al. Factors associated with impaired clinical status in long-term survivors of tetralogy of Fallot repair evaluated by magnetic resonance imaging. J Am Coll Cardiol. 2004;43(6):1068-1074. DOI: 10.1016/j.jacc.2003.10.045. PMID: 15028364.
Therrien J, Provost Y, Merchant N, et al. Optimal timing for pulmonary valve replacement in adults after tetralogy of Fallot repair. Am J Cardiol. 2005;95(6):779-782. DOI: 10.1016/j.amjcard.2004.11.037. PMID: 15757618.
Kapusta L, Eveleigh RM, Poulino SE, et al. 22q11.2 deletion in patients with conotruncal heart defects: the impact on outcome and disease burden. Clin Genet. 2012;82(6):562-568. DOI: 10.1111/j.1399-0004.2011.01802.x. PMID: 21955163.
Davlouros PA, Niwa K, Webb G, Gatzoulis MA. The right ventricle in congenital heart disease. Heart. 2006;92(Suppl 1):i27-i38. DOI: 10.1136/hrt.2005.077438. PMID: 16543597.
Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease. J Am Coll Cardiol. 2019;73(12):e81-e192. DOI: 10.1016/j.jacc.2018.08.1029. PMID: 30121239.
Kirklin JW, Wallace RB, McGoon DC, DuShane JW. Early and late results after intracardiac repair of tetralogy of Fallot. Ann Surg. 1965;162(4):578-589. DOI: 10.1097/00000658-196510000-00005. PMID: 5318817.